IFRX

InflaRx N.V.

1.71 USD
+0.17 (+11.04%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

InflaRx N.V. stock is up 18.75% since 30 days ago. The next earnings date is Aug 8, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 28.57% of the previous 6 June’s closed higher than May. 100% of analysts rate it a buy.

About InflaRx N.V.

InflaRx N.V. discovers and develops inhibitors using C5a technology. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases.